|
|
楼主 |
发表于 14-5-2021 08:59 AM
|
显示全部楼层
本帖最后由 icy97 于 4-10-2021 05:58 AM 编辑
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | BIOALPHA HOLDINGS BHD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA OF UP TO 5% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PROPOSED PRIVATE PLACEMENT") | On behalf of the Board of Directors of Bioalpha, TA Securities Holdings Berhad wishes to announce that the Company proposes to undertake the Proposed Private Placement.
Please refer to the attachment below for further details on the announcement.
This announcement is dated 5 November 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3103017
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA OF UP TO 5% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PROPOSED PRIVATE PLACEMENT") | We refer to the announcements made on 5 November 2020 and 6 November 2020 in relation to the Proposed Private Placement (“Announcements”). Unless otherwise defined, the definitions set out in the Announcements shall apply herein.
On behalf of Bioalpha, TA Securities Holdings Berhad wishes to provide additional information in relation to the use of proceeds from the Proposed Private Placement. Further details are set out in the attachment below.
This announcement is dated 11 November 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3104132
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Private Placement | Details of corporate proposal | PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN BIOALPHA HOLDINGS BERHAD ("BIOALPHA") OF UP TO 5% OF THE ENLARGED NUMBER OF ISSUED SHARES IN BIOALPHA (EXCLUDING ANY TREASURY SHARES) PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT 2016 ("PRIVATE PLACEMENT") | No. of shares issued under this corporate proposal | 52,877,100 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.2500 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 1,110,420,832 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 135,809,745.500 | Listing Date | 26 Nov 2020 |
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 6,871 | 17,276 | 19,795 | 43,791 | | 2 | Profit/(loss) before tax | -10,441 | 3,516 | -23,946 | 6,816 | | 3 | Profit/(loss) for the period | -10,441 | 3,164 | -24,795 | 6,135 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -9,709 | 3,105 | -23,908 | 5,996 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.94 | 0.36 | -2.42 | 0.70 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1573 | 0.1922
|
Type | Announcement | Subject | OTHERS | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Collaborative Agreement between Bioalpha International Sdn. Bhd. a wholly-owned subsidiary of Bioalpha and Ritamix Global Limited | INTRODUCTION
The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that its wholly-owned subsidiary, Bioalpha International Sdn. Bhd. (“BISB”) had on 2 December 2020 entered into a Collaborative Agreement (“CA”) with Ritamix Global Limited (“Ritamix”) for BISB to manufacture and supply health supplement products for Ritamix to market in China (including Hong Kong) and South East Asia.
INFORMATION ON RITAMIX
Ritamix Global Ltd is a company listed on the main market of Hong Kong Stock Exchange (“HKEX”) with more than 37 years of track record, principally engaging in (i) distribution of animal feed additives and, to a lesser extent, human food ingredients; and (ii) manufacturing of animal feed additives premixes. The Company sourced over 300 brand products from over 70 suppliers of different brand names to promote and distribute their products in Malaysia. They also produced over 150 own brand animal feed additives premixes for sales in Malaysia and overseas.
SALIENT TERMS OF THE CA
Pursuant to the CA, BISB will act as the contract manufacturer for Ritamix in the development of health supplement products not limited to immunity and longevity products. The products are formulated and owned by Ritamix. Ritamix shall market and distribute the products in China (including Hong Kong) and South East Asia.
RATIONALE
The CA being incurred is part of the ordinary course of business.
INTERESTS OF DIRECTORS AND/OR SUBSTANTIAL SHAREHOLDERS AND/OR PERSON CONNECTED THEM
None of the Directors nor major shareholders of Bioalpha, or persons connected with them, has any interest, direct or indirect, in the CA.
FINANCIAL EFFECTS
The CA will not have any effect on the issued share capital and the substantial shareholders’ shareholdings in Bioalpha as the CA does not involve any issuance of new shares of Bioalpha. It is also not expected to have material effect on the net assets and gearing of Bioalpha Group for the financial year ending 31 December 2020.
APPROVAL REQUIRED
The CA is not subject to the approval of the shareholders of Bioalpha or any regulatory authorities.
STATEMENT BY BOARD OF DIRECTORS
The Board of Director of Bioalpha, having taken into consideration all aspects of the CA is of the opinion that the CA is in the best interest of Bioalpha Group.
This announcement is dated 2 December 2020. |
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-04122020-00002 | Subject | COLLABORATIVE AGREEMENT BETWEEN BIOALPHA INTERNATONAL SDN BHD, A WHOLLY OWNED SUBSIDIARY OF BIOALPHA HOLDINGS BERHAD AND RITAMIX GROUP LIMITED ("COLLABORATIVE AGREEMENT") | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - Additional Information on the Collaborative Agreement between Bioalpha International Sdn. Bhd. a wholly-owned subsidiary of Bioalpha and Ritamix Global Limited | Query Letter Contents | We refer to your Company’s announcement dated 2 December 2020, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:-
1. The commencement and expiry dates of the Collaborative Agreement and whether the Collaborative Agreements is subject to renewal, and if yes, the details of such renewal. 2. The risks in relation to the Collaboration Agreement. 3. The financial effect of the Collaborative Agreement on the earning per share of the Group. | Unless otherwise stated, all abbreviations used herein shall have the same meaning as those mentioned in the announcement dated 2 December 2020 in relation to the Collaborative Agreement (“Announcement”).
The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to inform that the Company has received Bursa Malaysia Securities Berhad’s request dated 4 December 2020 for additional information in relation to the Company’s announcement made on 2 December 2020. The additional information are as follows:
1. The commencement and expiry dates of the Collaborative Agreement and whether the Collaborative Agreement is subject to renewal, and if yes, the details of such renewal.
The Collaborative Agreement (“CA”) has commenced on 2 December 2020 for the initial contract period of 5 years (“Initial Contract Period”). The CA may be extended for a further period of 5 years to be mutually agreed by both Parties.
2. The risks in relation to the Collaboration Agreement.
Bioalpha does not expect any material risk arising from the CA other than the normal operational risk associated with the CA, which Bioalpha would take appropriate measures to mitigate.
3. The financial effect of the Collaborative Agreement on the earning per share of the Group.
Barring any unforeseen circumstances, the Board envisages the CA to contribute positively to the earnings per share of Bioalpha in the future.
This announcement is dated 4 December 2020. |
Type | Announcement | Subject | MULTIPLE PROPOSALS | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")(I) PROPOSED RIGHTS ISSUE OF SHARES; (II) PROPOSED RIGHTS ISSUE OF ICPS;(III) PROPOSED PLACEMENT OF ICPS;(IV) PROPOSED CONSTITUTION AMENDMENTS; AND(V) PROPOSED DEED POLL AMENDMENTS(COLLECTIVELY, THE "PROPOSALS") | On behalf of the Board of Directors of Bioalpha (“Board”), TA Securities Holdings Berhad (“TA Securities”) wishes to announce that the Company proposes to undertake the Proposals. Please refer to the attachment below for further details on the announcement.
This announcement is dated 19 January 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3122365
Type | Announcement | Subject | MEMORANDUM OF UNDERSTANDING | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN BIOALPHA INTERNATIONAL SDN BHD AND iHEAL MEDICAL SERVICES SDN BHD | The Board of Directors of Bioalpha wishes to announce that Bioalpha International Sdn Bhd (“BISB”), a wholly-owned subsidiary of Bioalpha, had on 25 January 2021 entered into a Memorandum of Understanding (“MOU”) with iHEAL Medical Services Sdn Bhd (“iHEAL”), which outlines the intention of both parties to work in collaboration to provide Covid-19 vaccination services to the public.
Kindly refer to the attached file for further information.
This announcement is dated 25 January 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123823
Type | Announcement | Subject | OTHERS | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY") - PROCUREMENT AND DISTRIBUTION AGREEMENT FOR VACCINES INCLUDING COVID-19 VACCINE | The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that Bioalpha International Sdn. Bhd. (“BISB”), a wholly-owned subsidiary of Bioalpha has on 25 January 2021 entered into a Procurement and Distribution Agreement (“Agreement”) with Shanghai Bukun Trading Co., Ltd (“SBTC”), a wholly-owned subsidiary of Sinopharm (Hainan) Health Industry Co., Ltd (“Sinopharm Hainan”) for the procurement and distribution of vaccines in Malaysia, including but not limited to the Covid-19 vaccine developed by Sinovac Biotech Co., Ltd. (“Sinovac Biotech”), subject to relevant authorities’ approvals which include the National Pharmaceutical Regulatory Agency (“NPRA”). This arrangement has also been endorsed by Sinovac Biotech with regards to the Covid-19 vaccine.
Kindly refer to the attached file for further information.
This announcement is dated 25 January 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123824
Type | Announcement | Subject | MEMORANDUM OF UNDERSTANDING | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN BIOALPHA INTERNATIONAL SDN BHD AND ZUELLIG PHARMA SDN BHD | The Board of Directors of Bioalpha wishes to announce that Bioalpha International Sdn Bhd (“BISB”), a wholly-owned subsidiary of Bioalpha, had on 22 January 2021 entered into a Memorandum of Understanding (“MOU”) with Zuellig Pharma Sdn Bhd (“ZP”) to facilitate the importation, warehousing and distribution of the Covid-19 vaccine in Malaysia.
Kindly refer to the attached file for further information.
This announcement is dated 25 January 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123825
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 21-10-2021 08:13 AM
|
显示全部楼层
Type | Announcement | Subject | TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
NON RELATED PARTY TRANSACTIONS | Description | BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "THE COMPANY")ACQUISITION OF A COMPANY NAMELY, GUIZHOU HONGBO SUPPLY CHAIN CO. LTD FOR CASH CONSIDERATION OF RMB20,000.00 EQUIVALENT TO RM12,851.00 BY ITS INDIRECT WHOLLY-OWNED SUBSIDIARY, BIOALPHA (HAINAN) HEALTH CO. LTD. |
1. INTRODUCTION
This is a voluntary announcement pursuant to Rule 10.05(2) of the Ace Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that its indirect wholly-owned subsidiary, Bioalpha (Hainan) Health Co. Ltd. (“BHBL”) had on 20 October 2021 completed the acquisition of a company namely Guizhou Hongbo Supply Chain Co. Ltd. (“Guizhou Hongbo”) for a total cash purchase consideration of RMB20,000.00 equivalent to RM12,851.00. (“Acquisition”).
Following the Acquisition, Guizhou Hongbo will become a 100% owned subsidiary of BHBL and indirect 100% wholly owned subsidiary of Bioalpha.
2. INFORMATION ON GUIZHOU HONGBO
Guizhou Hongbo was incorporated on 31 March 2021 at 7th floor, Liu Gang building, Xiangyang Road, Zhazuo Street, Xiuwen District, Guiyang City, Guizhou Province, China. Their business operations included supply chain management services that involved food processing and productions, food management, general tradings which includes import and exports, agricultural related services and warehousing. The Director and the shareholder of Guizhou Hongbo is Mr Yao Hong. The registered capital of Guizhou Hongbo is RMB2,000,000.
3. SOURCE OF FUNDING
The Acquisition will be funded via the Company’s internally generated funds.
4. LIABILITIES TO BE ASSUMED
Save for the liabilities in the financial statements of Guizhou Hongbo, which will be consolidated into the results of the Company’s Group of Companies, there are no other liabilities including contingent liabilities and guarantees, to be assumed by the Company arising from the Acquisition.
5. RATIONALE OF THE ACQUISITION
The Acquisition will provide to Bioalpha Group opportunity to participate in health food and ingredients supply and to facilitate trading activities in Guizhou province.
6. APPROVAL REQUIRED
The Acquisition is not subject to the approval from the shareholders of Bioalpha or any other relevant regulatory authorities and/or parties.
7. INTEREST OF DIRECTORS, MAJOR SHAREHOLDERS AND/OR PERSON CONNECTED TO THEM
None of the Directors and/or Major Shareholders of Bioalpha and/or persons connected to them have any interest, direct or indirect, in the Acquisition.
8. FINANCIAL EFFECTS
8.1 Share capital and substantial shareholders’ shareholdings
The Acquisition will not have any effect on the issued and paid-up share capital of Bioalpha and the shareholding of its substantial shareholders as the Acquisition does not entail any issuance of new ordinary shares in the Company and/or convertible securities in the Company.
8.2 Net assets and gearing
The Acquisition will not have any immediate material effect on the net assets of Bioalpha Group for the financial year ending 31 December 2021.
8.3 Earnings per share (“EPS”)
The Acquisition is not expected to have a material effect on the consolidated earnings and EPS of Bioalpha Group.
9. DIRECTORS’ RECOMMENDATION
The Board, having considered all aspects of the Acquisition, including the rationale and benefits of the Acquisition, is of the opinion that the Acquisition is in the best interest of the Bioalpha Group.
10. HIGHEST PERCENTAGE RATIO APPLICABLE TO THE ACQUISITION
The highest percentage ratio applicable to the Acquisition pursuant to Rule 10.02(g) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad is 0.01% based on the audited consolidated financial statements of Bioalpha for the financial year ended 31 December 2020.
11. DOCUMENT FOR INSPECTION
The SSA is available for inspection at the registered office of the Company at Level 5, Block B, Dataran PHB, Saujana Resort, Section U2, 40150 Shah Alam, Selangor, during normal working hours from Monday to Friday (except Saturday, Sunday and Public Holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 20 October 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 12-1-2022 08:29 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2021 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2021 | 30 Sep 2020 | 30 Sep 2021 | 30 Sep 2020 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 28,368 | 6,871 | 82,895 | 19,795 | | 2 | Profit/(loss) before tax | 1,833 | -10,441 | 4,965 | -23,946 | | 3 | Profit/(loss) for the period | 1,499 | -10,441 | 4,445 | -24,795 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 1,573 | -9,709 | 4,561 | -23,908 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.13 | -0.94 | 0.40 | -2.42 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1593 | 0.1641
|
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 27-2-2022 08:41 AM
|
显示全部楼层
Expiry/Maturity of the securities
Instrument Category | Securities of PLC | Instrument Type | Warrants | Type Of Expiry | Expiry/Maturity of the securities | Mode of Satisfaction of Exercise/Conversion price | Cash | Exercise/ Strike/ Conversion Price | Malaysian Ringgit (MYR) 0.2200 | Exercise/ Conversion Ratio | 1:1 | Settlement Type / Convertible into | Physical (Shares) | Last Date & Time of Trading | 20 Dec 2021 05:00 PM | Date & Time of Suspension | 21 Dec 2021 09:00 AM | Last Date & Time for Transfer into Depositor's CDS a/c | 29 Dec 2021 04:30 PM | Date & Time of Expiry | 05 Jan 2022 05:00 AM | Date & Time for Delisting | 06 Jan 2022 09:00 AM |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3216182
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 22-9-2022 08:56 AM
|
显示全部楼层
Notice of Person Ceasing (Section 139 of CA 2016)Particulars of Substantial Securities HolderName | MR HON TIAN KOK@WILLIAM | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary Share | Name of registered holder | TA Nominees (Tempatan) Sdn Bhd Pledged Securities Account for Hon Tian Kok @ William | Date of cessation | 20 Sep 2022 |
No of securities disposed | 68,000,000 | Circumstances by reason of which a person ceases to be a substantial shareholder | Disposal of ordinary shares via off market | Nature of interest | Direct Interest |  | Date of notice | 21 Sep 2022 | Date notice received by Listed Issuer | 21 Sep 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 5-9-2023 08:17 AM
|
显示全部楼层
Date of change | 04 Sep 2023 | Name | DATO' HAJI MOHD YAZID BIN HAJI MUSTAFA | Age | 66 | Gender | Male | Nationality | Malaysia | Designation | Non Executive Chairman | Directorate | Independent and Non Executive | Type of change | Appointment |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Degree | Bachelor of Laws | Universiti of Malaya | | | 2 | Others | High School Certificate | Sekolah Tunku Abdul Rahman, Ipoh (STAR_ | |
Working experience and occupation | A High Court Judge for more than 15 years, Dato' Haji Mohd Yazid bin Haji Mustafa retired from the Judiciary service in December 2022.Prior to his judgeship, Dato' Haji Mohd Yazid bin Haji Mustafa served in various capacities both in courts and the Attorney Generals Chambers such as Sessions Court Judge, Magistrate, Senior Assistant Registrar of High Court, Deputy Public Prosecutor, Senior Federal Counsel, Chairman of the Cooperative Tribunal and Registrar of High Court.Post-retirement, Dato' Haji Mohd Yazid bin Haji Mustafa continues to serve as a court of Appeal judge of the Terengganu Syariah CourtsDato' Haji Mohd Yazid bin Haji Mustafa offers broad range of legal services including counsel work, advisory and strategies. | Directorships in public companies and listed issuers (if any) | LKL International Berhad |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 14-8-2024 06:40 AM
|
显示全部楼层
Date of change | 31 Jul 2024 | Name | MISS GOH SIOW CHENG | Age | 42 | Gender | Female | Nationality | Malaysia | Type of change | Others | Designation | Chief Financial Officer | Description | Ms Goh has resigned as Executive Director of the Company. Her role as Group Chief Financial Officer of the Company remains. |
Qualifications| No | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Degree | Bachelor of Business (Accounting & Finance) | University of Technology Sydney, Australia | | | 2 | Professional Qualification | member of CPA | Australia. | |
| | | Working experience and occupation | Ms. Goh is one of the key senior staff members involved in the group's listing exercise. She has responsibly and effectively led her team to take on various corporate exercises, investment, and acquisition projects for the Group.Ms. Goh has more than 10 years of experience in audit and assurance from a large international accounting firm where she was involved in audits for both private limited companies and public listed companies across various industries, including manufacturing, trading, property development, information technology and plantation.Ms Goh currently sits on the Board of BTM Resources Berhad. |
|
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 16-9-2024 05:48 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2024 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2023 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 22,962 | 8,513 | 30,184 | 17,044 | | 2 | Profit/(loss) before tax | -7,831 | -3,584 | -15,095 | -20,376 | | 3 | Profit/(loss) for the period | -7,837 | -3,734 | -15,099 | -20,526 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -7,406 | -3,371 | -14,668 | -20,163 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.53 | -0.27 | -1.04 | -1.60 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0945 | 0.1028
|
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
1211 
23
